Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Radium-223; mCRPC, asymptomatic; Bone metastases

Detalles Bibliográficos
Autores: Heidenreich, Axel, Keizman, Daniel, O'Sullivan, Joe M, Carles Galceran, Joan, Heinrich, Daniel, Gillessen, Silke
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:11351/3786
Acceso en línea:https://hdl.handle.net/11351/3786
Access Level:acceso abierto
Palabra clave:Metàstasi
Ossos - Càncer
Càncer - Radioteràpia
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Neoplasms, Connective Tissue::Neoplasms, Bone Tissue
CHEMICALS AND DRUGS::Inorganic Chemicals::Elements::Inorganic Chemicals::Elements::Metals, Alkaline Earth::Inorganic Chemicals::Elements::Inorganic Chemicals::Inorganic Chemicals::Inorganic Chemicals::Radium
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias óseas
COMPUESTOS QUÍMICOS Y DROGAS::compuestos inorgánicos::elementos::compuestos inorgánicos::elementos::metales alcalinotérreos::compuestos inorgánicos::elementos::compuestos inorgánicos::compuestos inorgánicos::compuestos inorgánicos::radio (elemento)
Otros calificadores::Otros calificadores::/uso terapéutico
id ES_4e620f6e90d7f84ffc86870f09426f5b
oai_identifier_str oai:recercat.cat:11351/3786
network_acronym_str ES
network_name_str España
repository_id_str
dc.title.none.fl_str_mv Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
title Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
spellingShingle Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Heidenreich, Axel
Metàstasi
Ossos - Càncer
Càncer - Radioteràpia
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Neoplasms, Connective Tissue::Neoplasms, Bone Tissue
CHEMICALS AND DRUGS::Inorganic Chemicals::Elements::Inorganic Chemicals::Elements::Metals, Alkaline Earth::Inorganic Chemicals::Elements::Inorganic Chemicals::Inorganic Chemicals::Inorganic Chemicals::Radium
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias óseas
COMPUESTOS QUÍMICOS Y DROGAS::compuestos inorgánicos::elementos::compuestos inorgánicos::elementos::metales alcalinotérreos::compuestos inorgánicos::elementos::compuestos inorgánicos::compuestos inorgánicos::compuestos inorgánicos::radio (elemento)
Otros calificadores::Otros calificadores::/uso terapéutico
title_short Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
title_full Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
title_fullStr Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
title_full_unstemmed Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
title_sort Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
dc.creator.none.fl_str_mv Heidenreich, Axel
Keizman, Daniel
O'Sullivan, Joe M
Carles Galceran, Joan
Heinrich, Daniel
Gillessen, Silke
author Heidenreich, Axel
author_facet Heidenreich, Axel
Keizman, Daniel
O'Sullivan, Joe M
Carles Galceran, Joan
Heinrich, Daniel
Gillessen, Silke
author_role author
author2 Keizman, Daniel
O'Sullivan, Joe M
Carles Galceran, Joan
Heinrich, Daniel
Gillessen, Silke
author2_role author
author
author
author
author
dc.contributor.none.fl_str_mv Institut Català de la Salut
[Heidenreich A] Department of Urology, University Hospital Cologne, Cologne, Germany. [Gillessen S] Division of Cancer Sciences, University of Manchester and the Christie, Manchester, UK. Medical Oncology and Haematology, Kantonsspital St Gallen, St Gallen, Switzerland. University of Bern, Bern, Switzerland. [Heinrich D] Department of Oncology, Akershus University Hospital, Lørenskog, Norway. [Keizman D] Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Kfar-Saba, Israel. [O'Sullivan JM] Department of Clinical Oncology, The Centre for Cancer Research and Cell Biology, Queen's University Belfast and the Northern Ireland Cancer Centre, Belfast, Northern Ireland, UK. [Carles J] Servei d'Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d'Hebron Institut d'Oncologia, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
dc.subject.none.fl_str_mv Metàstasi
Ossos - Càncer
Càncer - Radioteràpia
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Neoplasms, Connective Tissue::Neoplasms, Bone Tissue
CHEMICALS AND DRUGS::Inorganic Chemicals::Elements::Inorganic Chemicals::Elements::Metals, Alkaline Earth::Inorganic Chemicals::Elements::Inorganic Chemicals::Inorganic Chemicals::Inorganic Chemicals::Radium
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias óseas
COMPUESTOS QUÍMICOS Y DROGAS::compuestos inorgánicos::elementos::compuestos inorgánicos::elementos::metales alcalinotérreos::compuestos inorgánicos::elementos::compuestos inorgánicos::compuestos inorgánicos::compuestos inorgánicos::radio (elemento)
Otros calificadores::Otros calificadores::/uso terapéutico
topic Metàstasi
Ossos - Càncer
Càncer - Radioteràpia
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Neoplasms, Connective Tissue::Neoplasms, Bone Tissue
CHEMICALS AND DRUGS::Inorganic Chemicals::Elements::Inorganic Chemicals::Elements::Metals, Alkaline Earth::Inorganic Chemicals::Elements::Inorganic Chemicals::Inorganic Chemicals::Inorganic Chemicals::Radium
Other subheadings::Other subheadings::/therapeutic use
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias óseas
COMPUESTOS QUÍMICOS Y DROGAS::compuestos inorgánicos::elementos::compuestos inorgánicos::elementos::metales alcalinotérreos::compuestos inorgánicos::elementos::compuestos inorgánicos::compuestos inorgánicos::compuestos inorgánicos::radio (elemento)
Otros calificadores::Otros calificadores::/uso terapéutico
description Radium-223; mCRPC, asymptomatic; Bone metastases
publishDate 2019
dc.date.none.fl_str_mv 2019
2019
2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11351/3786
url https://hdl.handle.net/11351/3786
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv BMC Cancer;19(1)
https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-5203-y
dc.rights.none.fl_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv BMC
publisher.none.fl_str_mv BMC
dc.source.none.fl_str_mv Scientia
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869407752865972224
spelling Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access programHeidenreich, AxelKeizman, DanielO'Sullivan, Joe MCarles Galceran, JoanHeinrich, DanielGillessen, SilkeMetàstasiOssos - CàncerCàncer - RadioteràpiaDISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms, Connective and Soft Tissue::Neoplasms, Connective Tissue::Neoplasms, Bone TissueCHEMICALS AND DRUGS::Inorganic Chemicals::Elements::Inorganic Chemicals::Elements::Metals, Alkaline Earth::Inorganic Chemicals::Elements::Inorganic Chemicals::Inorganic Chemicals::Inorganic Chemicals::RadiumOther subheadings::Other subheadings::/therapeutic useENFERMEDADES::neoplasias::neoplasias por localización::neoplasias óseasCOMPUESTOS QUÍMICOS Y DROGAS::compuestos inorgánicos::elementos::compuestos inorgánicos::elementos::metales alcalinotérreos::compuestos inorgánicos::elementos::compuestos inorgánicos::compuestos inorgánicos::compuestos inorgánicos::radio (elemento)Otros calificadores::Otros calificadores::/uso terapéuticoRadium-223; mCRPC, asymptomatic; Bone metastasesRadio-223; mCRPC, asintomático; Metástasis de huesoRadi-223; mCRPC, asimptomàtic; Metàstasis d'osBACKGROUND: Radium-223, a targeted alpha therapy, is used to treat symptomatic patients with castration-resistant prostate cancer (CRPC) and bone metastases. Data for radium-223 in asymptomatic CRPC patients with bone metastases are lacking. METHODS: This was a prospective, single-arm phase 3b study. Patients with metastatic CRPC (malignant lymphadenopathy not exceeding 6 cm was allowed, visceral disease was excluded) received radium-223, 55 kBq/kg intravenously, every 4 weeks for up to 6 cycles. Co-primary endpoints were safety and overall survival. Post hoc analyses were performed according to baseline asymptomatic or symptomatic disease status. Asymptomatic status was defined as no pain and no opioid use at baseline. RESULTS: Seven hundred eight patients received ≥1 radium-223 injection: 548 (77%) were symptomatic to various degrees, and 135 (19%) were asymptomatic. Asymptomatic patients had more favorable baseline disease characteristics than symptomatic. A lower proportion of asymptomatic versus symptomatic patients had received prior abiraterone (25% vs 35%) and prior docetaxel (52% vs 62%). A higher proportion of asymptomatic (71%) versus symptomatic (55%) patients completed radium-223 treatment. Overall survival (hazard ratio [HR] 0.486), time to disease progression (HR 0.722) and time to first symptomatic skeletal event (HR 0.328) were better in asymptomatic than symptomatic patients. Alkaline phosphatase (ALP) response rates were similar (46% vs 47%), and ALP normalization (44% vs 25%) and prostate-specific antigen response rates (21% vs 13%) were higher in asymptomatic than symptomatic patients. A lower proportion of asymptomatic patients reported treatment-emergent adverse events (TEAEs, 61% vs 79%), grade 3-4 TEAEs (29% vs 40%) and drug-related TEAEs (28% vs 44%). There were two treatment-related deaths, both in patients with baseline symptomatic disease. CONCLUSIONS: Using radium-223 earlier in the disease course, when patients are asymptomatic or minimally symptomatic, may enable patients to complete treatment and optimize treatment outcome compared to symptomatic patients, and therefore may allow sequencing with other life-prolonging therapiesBMCInstitut Català de la Salut[Heidenreich A] Department of Urology, University Hospital Cologne, Cologne, Germany. [Gillessen S] Division of Cancer Sciences, University of Manchester and the Christie, Manchester, UK. Medical Oncology and Haematology, Kantonsspital St Gallen, St Gallen, Switzerland. University of Bern, Bern, Switzerland. [Heinrich D] Department of Oncology, Akershus University Hospital, Lørenskog, Norway. [Keizman D] Genitourinary Oncology Service, Institute of Oncology, Meir Medical Center, Kfar-Saba, Israel. [O'Sullivan JM] Department of Clinical Oncology, The Centre for Cancer Research and Cell Biology, Queen's University Belfast and the Northern Ireland Cancer Centre, Belfast, Northern Ireland, UK. [Carles J] Servei d'Oncologia Mèdica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. Vall d'Hebron Institut d'Oncologia, Barcelona, SpainVall d'Hebron Barcelona Hospital Campus201920192019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://hdl.handle.net/11351/3786Scientiareponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésBMC Cancer;19(1)https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-5203-yAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessoai:recercat.cat:11351/37862026-05-29T05:05:01Z
score 15,811543

Similares en LA Referencia